A TMC-based organization supporting innovation pediatric medical devices has secured a $7.4 million grant. Photo via tmc.edu

The Southwest National Pediatric Device Innovation Consortium announced this month that it has received a $7.4 million grant from the Food and Drug Administration to continue developing innovative pediatric medical devices.

Led by Baylor College of Medicine and Texas Children’s Hospital, SWPDC supports the development and commercialization of devices relating to children's health, including synthetic pediatric heart valves, miniature injection devices and neonatal intensive care unit monitoring devices, according to a statement from Baylor.

According to Dr. Chester Koh, SWPDC executive director and principal investigator, who is also a professor of urology at Baylor and a pediatric urologist at Texas Children’s, physicians today often have to treat pediatric patients with devices that are designed for larger adult bodies.

"This grant allows us to continue to spur development of devices specifically designed for kids by providing funding, consulting, clinical expertise and other assistance, all of which is made possible by our co-existence in the healthcare innovation ecosystem of the Texas Medical Center,” he said in the statement.

The SWPDC received a similar five-year grant in 2018 from the FDA, and has since added 200 pediatric device projects in all stages of development to its portfolio, raising in total more than $200 million in follow-on funding for the technology. It's one of five consortia in the FDA’s Pediatric Device Consortia (PDC), with others in Pennsylvania, Washington D.C., the San Francisco Bay Area, and Los Angeles.

Regionally, the consortium members include engineers from Texas A&M University, Rice University, University of Houston and the University of Minnesota, as it looks to expand into the midwest. It also partners with Texas Medical Center Innovation, JLABS@TMC and Proxima CRO.

In addition to the $7.4 million grant, SWPDC also received funding for its real-world data/real-world evidence (RWD/RWE) demonstration projects that focus on postoperative cardiac care, according to BCM.

Earlier this summer, Houston-based medtech company CorInnova was one of five companies invited to invited to present pitches at the National Capital Consortium for Pediatric Device Innovation’s “Make Your Medical Device Pitch for Kids!” competition. The event takes place this month and the companies are competing for a share of $150,000 in grant funding from the FDA. CorInnova has developed a minimally invasive device for the treatment of congestive heart failure.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.